Advertisements

Clamoxol Duo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Clamoxol Duo

Quick Facts

Property Description
Active Ingredients Amoxicillin, Clavulanic Acid
Form Tablets, Oral Suspension, IV Powder
Pharmacological Class beta-Lactam/beta-Lactamase Inhibitor combination
General Purpose Eradication of susceptible bacterial infections
Origin Synthetic

What Type of Medicine is Clamoxol Duo?

Clamoxol Duo is a synthetic and fixed-dose combination medicine, known generically as co-amoxiclav or Amoxicillin-Clavulanate, officially classified as an Anti-infective for systemic use. This preparation belongs to the beta-Lactam/beta-Lactamase Inhibitor combination group. The core component, Amoxicillin, is an established penicillin-class antibiotic. This medicine is typically manufactured for use in both adults and pediatric populations, necessitating the variety of available forms. It is supplied in multiple pharmaceutical preparations, including film-coated tablets, dispersible tablets, and a powder for solution suitable for oral or intravenous administration, depending on the required delivery route.


Composition: Why Does Clamoxol Duo Have Two Ingredients?

The effectiveness of the medicine stems from its two distinct active ingredients: Amoxicillin and Clavulanic Acid, which are combined to achieve a functional synergy. Amoxicillin provides the core bactericidal action by disrupting the structures that bacteria need to build their cell walls. The secondary component, Clavulanic Acid (often present as Potassium Clavulanate), is not an antibiotic but functions as an enzyme inhibitor. Clavulanic Acid neutralizes beta-lactamase, the bacterial defense mechanism that destroys Amoxicillin. This protective action ensures that the Amoxicillin remains viable, giving the medicine a much broader scope of action against various bacteria, extending its utility over older, single-ingredient penicillins. The general therapeutic purpose of this unique pairing is to effectively achieve pathogen eradication and clear a wide range of bacterial infections that might otherwise resist Amoxicillin if used alone.

Regulatory References

  1. U.S. National Library of Medicine (MedlinePlus)
  2. Amoxicillin and Clavulanate Potassium
Advertisements

What side effects are possible with Clamoxol Duo?

Possible Side Effects and Safety Information

Clamoxol Duo (amoxicillin/clavulanate potassium) has a documented safety profile derived from regulatory-approved labeling. All patients should be aware of the potential for both common and serious adverse reactions.


Adverse Reaction Scope

Classification Adverse Reactions (Select Examples) Notes/Regulatory Frequency
Most Common Diarrhea, nausea, vomiting, skin rash, vaginitis. Diarrhea reported in approximately 9% of patients in clinical trials (Immediate-release formulation).
Serious/Severe Anaphylaxis, Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Acute Generalized Exanthematous Pustulosis (AGEP). Severe Cutaneous Adverse Reactions (SCAR) require close monitoring and immediate discontinuation if lesions progress.
Gastrointestinal Clostridium difficile-associated diarrhea (CDAD) and Drug-induced enterocolitis syndrome (DIES). CDAD can occur during or after therapy and necessitates evaluation if severe diarrhea develops.
Hepatobiliary Hepatic dysfunction, including cholestatic jaundice and hepatitis. Can be fatal in rare cases; requires monitoring of liver function tests.

Key Safety Restrictions and Considerations

Contraindications

The drug is formally contraindicated in individuals with a history of a serious hypersensitivity reaction (e.g., anaphylaxis or SJS) to Clamoxol Duo or to other beta-lactam antibiotics (e.g., penicillins, cephalosporins). It is also contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with previous exposure to the medication.

Warnings and Precautions

  • Hypersensitivity: Treatment must be discontinued immediately if any severe allergic reaction occurs.
  • Hepatic/Renal Impairment: Patients with severe renal impairment require dosage adjustments. Use in patients with hepatic impairment requires discontinuation if signs of hepatitis occur.
  • Other Populations: The drug is typically avoided in patients with mononucleosis due to a high incidence of skin rash.
  • Interactions: Clamoxol Duo may reduce the efficacy of oral contraceptives and may prolong prothrombin time when coadministered with oral anticoagulants, requiring appropriate laboratory monitoring.
Advertisements

Overdose and Emergency Response

Overdose with Clamoxol Duo (Amoxicillin-Clavulanate) is officially documented as primarily causing gastrointestinal distress. Documented overdose manifestations include nausea, vomiting, diarrhea, and stomach pain. Central nervous system (CNS) signs such as hyperactivity and drowsiness are also reported. Manifestations related to kidney function, such as decreased urination, have also been cited in regulatory information.

When to Seek Urgent Help

It is mandated that individuals seek emergency medical attention immediately or call a Poison Help line upon known or suspected overdose. Urgent medical attention is required if severe symptoms occur, including signs of an allergic reaction (such as difficulty breathing), or if the patient experiences a seizure or is unable to be awakened.

Severe Outcomes and Management

The most serious potential outcome identified in the regulatory profile is crystalluria, which can potentially lead to acute renal failure. This risk is heightened in patients with pre-existing impaired renal function or those exposed to very high doses. Management is generally symptomatic and supportive. Regulatory documents state that hemodialysis is a procedure that may be utilized to remove the active ingredients from the bloodstream, as no specific antidote is known.

Advertisements

Therapeutic Uses of Clamoxol Duo

What Clamoxol Duo Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed, primarily for conditions where symptoms may intensify temporarily due to bacterial infection. It is used in the treatment of conditions such as Lower Respiratory Tract Infections, Acute Bacterial Otitis Media (ear infections), Sinusitis, Skin and Skin Structure Infections, and Urinary Tract Infections.

It is commonly used when symptom clusters appear suddenly or create noticeable physiological strain, applied in contexts where additional symptomatic support is needed. It helps ease the overall symptom burden by supporting the patient during episodes of heightened discomfort and managing systemic malaise like fever and acute localized pain.

“This medicine is relevant for managing symptoms associated with significant inflammatory processes across various tissue sites.”

The medication assists with easing the overall symptom load and supports patients through difficult episodes.


Quick Fact: Contexts of Use for Acute Symptoms
This combination is applied when conditions involve inflammatory or irritative states leading to fever, acute localized pain, and symptoms that interfere with daily functioning in the respiratory tract, skin, and urinary system.
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Clamoxol Duo (Amoxicillin/Clavulanic Acid)

Clamoxol Duo's eligibility is strictly determined by regulatory documentation, focusing on contraindications and specific patient characteristics. This information should not be interpreted as medical advice.


Contraindications: Who Must Not Use It

Use of Clamoxol Duo is absolutely prohibited in patients with:

  • A known history of severe immediate hypersensitivity (e.g., anaphylaxis or Stevens-Johnson syndrome) to penicillins (including amoxicillin) or other beta-lactam antibiotics (e.g., cephalosporins).
  • A history of jaundice or hepatic dysfunction previously associated with amoxicillin/clavulanic acid use.

Eligibility-Related Restrictions

Population/Condition Restriction Status Regulatory Basis
Infectious Mononucleosis Use not recommended (increased risk of rash). Specific Warning
Severe Renal Impairment Restricted use (requires dose adjustment; some high-dose forms are prohibited). Special Precaution
Pregnancy/Lactation Avoided unless deemed essential; use with caution while breastfeeding. Special Population Precaution
Infants < 3 Months Use is limited; safety and efficacy are not fully established. Age-Group Limitation

Eligibility is also contingent on the absence of phenylketonuria (PKU) if the specific formulation contains aspartame, and caution is required in all patients with any degree of hepatic impairment.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clamoxol Duo (amoxicillin/clavulanate) may interact with certain medicines, requiring careful monitoring or a change in therapy. It is essential to inform your doctor or pharmacist of all current prescription, over-the-counter, and herbal products you are taking.

Interacting Product Category Key Interaction Context
Oral Anticoagulants (e.g., Warfarin) Increased risk of bleeding. The combination may prolong the prothrombin time (INR), necessitating close monitoring of coagulation tests.
Methotrexate Risk of increased toxicity from Methotrexate due to reduced kidney clearance of the drug. Monitoring is typically required.
Probenecid Concomitant use is generally not recommended as Probenecid can decrease the kidney removal of amoxicillin, resulting in higher and prolonged blood levels of amoxicillin.
Allopurinol Increased risk of developing an allergic skin rash.
Oral Contraceptives (Birth Control Pills) May reduce the effectiveness of oral contraceptives. A non-hormonal, backup method of birth control may be advised during treatment.

This medicine can also interfere with certain medical tests. Specifically, amoxicillin may cause a false-positive result in non-enzymatic urine glucose tests and in some tests for the presence of Aspergillus antigen.

Advertisements

Mechanism of Action

Clamoxol Duo combines two distinct molecules: amoxicillin and clavulanic acid.

Amoxicillin, a beta-lactam antibiotic, acts as an inhibitor by covalently binding to bacterial penicillin-binding proteins (PBPs), specifically the DD-transpeptidases. These PBPs are critical enzymes located on the inner membrane that catalyze the final cross-linking steps in the biosynthesis of the peptidoglycan layer, which is essential for bacterial cell wall integrity. The binding event inactivates the PBPs, disrupting the polymerization and cross-linking of the peptidoglycan matrix. This molecular disruption arrests cell wall construction. The intracellular consequence is the activation of bacterial autolytic enzymes (autolysins), which, combined with the structural deficiency of the cell wall, leads to subsequent bacterial lysis and loss of cellular integrity.

Clavulanic acid has negligible intrinsic antimicrobial activity. It functions as a mechanism-based suicide inhibitor of beta-lactamase enzymes produced by some bacterial strains. The beta-lactamase enzyme normally hydrolyzes the beta-lactam ring of amoxicillin, rendering it inactive. Clavulanic acid binds to the active site of beta-lactamase, forming a stable covalent intermediate that permanently inactivates the enzyme. This inhibition prevents the enzymatic degradation of amoxicillin, thereby maintaining the effective concentration of amoxicillin at its bacterial PBP targets and allowing the downstream bacteriolytic cascade to proceed. The system-level physiological consequence is the preservation of amoxicillin's functional inhibitory activity against susceptible bacteria.

Advertisements

Dosage and Administration Information

How to Use Clamoxol Duo: Official Administration Guidelines

Clamoxol Duo (Amoxicillin/Clavulanate) is utilized through two main official routes of administration: the oral route for tablets and suspension, and the intravenous (IV) route for the injectable powder, typically reserved for more severe infections or hospital settings.

Administration is governed by fixed scheduling patterns, usually requiring dosing every 12 hours (Twice Daily) or every 8 hours (Three Times Daily), depending on the chosen formulation and the condition being addressed. The duration of use is standardized, typically spanning 7 to 10 days, and guidance advises that treatment should not be extended beyond 14 days without clinical review.

Key Administration Constraints

Feature Procedural Instruction
Timing with Food Oral forms must be taken at the start of a meal to enhance the absorption of the clavulanate component and improve tolerability.
Special Handling Extended-Release tablets must be swallowed whole and must not be crushed, broken, or chewed.
Dosing in Renal Impairment Patients with a Glomerular Filtration Rate (GFR) le 30 mL/min require mandatory dose adjustment, and the high-strength/extended-release tablets are typically not recommended.
Missed Dose If a dose is missed, it should be taken as soon as possible, but the patient must not take two doses together to make up for the missed one.

For pediatric patients under 40 kg, dosing is precisely calculated based on the child's body weight (mg/kg/day) of the amoxicillin component, divided across the standard daily administration intervals. The overall protocol for using this medicine emphasizes strict adherence to both the scheduled interval and the contextual instructions to maintain standardized treatment.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clamoxol Duo

Evidence for Use in Lower Respiratory Tract Infections (LRTIs)

Research related to Lower Respiratory Tract Infections (LRTIs), which include conditions such as Community-Acquired Pneumonia (CAP), was evaluated using Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies were used in research exploring how outcomes related to functional imbalance change over time in observed populations. Outcomes monitored in these studies included the rates of outcomes related to clinical status or resolution at the end of treatment and measurements of serious outcomes such as hospital readmission and mortality.

The clinical trials included diverse patient groups, such as adults (including older adults) and children. The findings describe patterns observed in the studies related to how patients recovered during the study period. Some reports described the rates of treatment failure compared to other therapeutic approaches. The evidence derived from these settings data show patterns related to measurements related to clinical resolution when studied for these conditions.

Evidence for Use in Acute Otitis Media (AOM)

The evidence summary here describes the structure of comparative clinical trials focused on pediatric populations, outlining the study designs used to measure endpoints such as the time to symptom relief and the rates of re-treatment for ear infections. Studies monitored endpoints such as the time to symptom relief (for fever and pain) and the rates of re-treatment or clinical failure.

Research describes patterns related to clinical status in the observed pediatric populations. However, research is ongoing to assess the findings when this medicine is compared against older treatments due to the continuous evolution of microbial resistance patterns. Also, the findings were mixed or uncertain in some subgroups, as studies focusing on uncomplicated cases sometimes lacked microbiological confirmation of the infection.

What the Research Still Shows as Uncertain

A key limitation is that comparative evidence is lacking or mixed in some settings, such as research exploring whether an incremental advantage over older, single-ingredient treatments is observed for every patient and every severity level. Long-term effects are not fully established, as follow-up durations were limited in many pivotal clinical trials. Furthermore, data for certain complex groups, such as those with specific coexisting conditions (comorbidities), remain insufficient.

Key Studies & References

  1. Effectiveness of amoxicillin and amoxicillin-clavulanate for the treatment of community-acquired pneumonia in adults and children: systematic review and network meta-analysis (medRxiv Preprint/WHO rationale)
  2. Otitis media (acute): antimicrobial prescribing (NICE Guideline NG91)
  3. Infectious Disease Society of America (IDSA) Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Clamoxol Duo (FAQ)


Q: What is Clamoxol Duo prescribed for, generally?

A: Clamoxol Duo is officially prescribed for the treatment of specific bacterial infections that are susceptible to the medicine. These commonly include infections of the lower respiratory tract, acute bacterial otitis media (ear infections), urinary tract infections, and infections affecting the skin and soft tissue. The medicine is intended only for the treatment of these confirmed bacterial infections.


Q: Is Clamoxol Duo the same thing as a regular antibiotic?

A: No, it is a combination product. Unlike a single-ingredient antibiotic, it contains two components: the antibiotic Amoxicillin and Clavulanic Acid, which protects the Amoxicillin. This combination is designed to work against a broader range of bacteria, including those that have developed defenses against Amoxicillin alone.


Q: Is it normal to feel tired while taking Clamoxol Duo?

A: Fatigue or tiredness is not typically listed as a common or very common side effect in the official product information. However, some documented adverse effects affect the central nervous system, such as dizziness. If unexpected or severe tiredness occurs, a discussion with a healthcare professional is generally advised.


Q: Can Clamoxol Duo be used for conditions other than infections?

A: According to regulatory documents, Clamoxol Duo is officially indicated only for the treatment of susceptible bacterial infections. Its approved uses are strictly limited to these purposes.


Q: What kind of infections is Clamoxol Duo used to treat?

A: The medicine is indicated for treating infections caused by certain bacteria, including conditions such as lower respiratory tract infections, acute bacterial sinusitis, acute otitis media, urinary tract infections, and infections of the skin and soft tissue. The medicine is generally used when an infection is caused by bacteria listed in the official prescribing information.


Q: How long does Clamoxol Duo typically stay in your system?

A: For adults with normal kidney function, the half-life for both Amoxicillin and Clavulanic acid is reported to be approximately 1 to 1.5 hours. The half-life refers to the time it takes for the amount of drug in the body to decrease by half. The clearance of the drug can be discussed with a healthcare professional.


Q: Is Clamoxol Duo safe to use during pregnancy, based on official information?

A: Official regulatory documents describe that use during pregnancy should generally be avoided unless a healthcare professional considers it essential. Its use is typically limited to cases where the potential benefit to the mother is judged to outweigh the potential risk to the fetus.


Q: Can Clamoxol Duo affect my ability to drive or operate machinery?

A: Some official documentation advises caution regarding driving or operating machinery. This is because side effects like dizziness or allergic reactions may occur, and these could potentially affect the ability to perform tasks requiring alertness.


Q: Does Clamoxol Duo interact with common pain relievers like ibuprofen?

A: Ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) are not listed as having a specific, direct interaction with Clamoxol Duo that would contraindicate their concurrent use in regulatory documents. However, any combination of medicines may be reviewed by a prescribing professional.


Q: Why is the medicine called 'Duo'?

A: The name 'Duo' is used to highlight that the medicine is a fixed-dose combination product. It indicates that the drug contains two distinct active ingredients: the antibiotic Amoxicillin and Clavulanic Acid.


Q: Is it important to take Clamoxol Duo for the full prescribed time?

A: Official information emphasizes that the full course of treatment should be completed, even if symptoms begin to improve early. Stopping the medicine too soon may reduce the effectiveness and may contribute to the development of bacterial resistance.


Q: Is Clamoxol Duo approved for use in older adults (seniors)?

A: Clamoxol Duo is approved for use in adults, including older adults. A specific consideration for older patients is necessary if they have reduced kidney function, as this may require a dosage adjustment to prevent drug buildup.


Q: Can Clamoxol Duo cause headaches or dizziness?

A: Headache and dizziness are listed in the official documentation as possible adverse effects. However, the frequency of these particular reactions is generally described as uncommon.


Q: Are there any known interactions between Clamoxol Duo and herbal supplements?

A: Official guidance often recommends caution regarding the use of herbal remedies and supplements. Safety data for their combination with the medicine is generally lacking, and a review of all such products with a healthcare professional before use is consistent with official guidance.


Q: What does the patient information leaflet say about Clamoxol Duo?

A: Patient Information Leaflets (PILs) are required to contain key, summarized facts about the medicine's proper use, important warnings, specific storage instructions, and documented side effects. They are designed to present the official prescribing information in a patient-friendly format.


Q: Is Clamoxol Duo suitable for people with diabetes?

A: The medicine is not generally restricted for use in people with diabetes. However, official information notes that it may cause a false-positive result in non-enzymatic urine glucose tests, which is a caution for patients using this type of test to monitor their condition.


Q: Are there any known long-term effects associated with Clamoxol Duo?

A: The official research summary notes that follow-up durations in many pivotal clinical trials were limited, meaning data on long-term outcomes are not fully established in that specific research context. Ongoing post-marketing surveillance helps monitor for any new effects.


Q: Is Clamoxol Duo a prescription-only medicine?

A: Yes, Clamoxol Duo (Amoxicillin/Clavulanate) is officially classified as a prescription-only medicine in most jurisdictions and requires a healthcare professional's authorization to obtain.


Q: What information is available about Clamoxol Duo and resistance development?

A: Regulatory documents define the medicine's unique composition as actively addressing bacterial resistance. The clavulanic acid component protects the amoxicillin from being inactivated by bacterial defense enzymes, which is its primary benefit against resistance.


Q: Do studies mention Clamoxol Duo being effective against certain types of bacteria?

A: Yes, the official documentation lists specific bacteria for which the medicine has demonstrated activity. This includes both beta-lactamase producing and non-producing strains known to cause the infections the medicine is indicated to treat.


Q: Are there different strengths of Clamoxol Duo tablets?

A: Yes, regulatory documents list several different available strengths of the tablets and oral suspension forms. These strengths vary in the ratio and total amounts of the amoxicillin and clavulanic acid components.


Q: Can I take Clamoxol Duo if I have a history of allergies to other drugs?

A: A history of allergy to other drugs is relevant. Specifically, the medicine is strictly prohibited if you have a history of a serious hypersensitivity reaction to any penicillin or other beta-lactam antibiotics, such as cephalosporins.


Q: Are there special considerations for using Clamoxol Duo in adolescents?

A: Adolescents who weigh over 40 kg (approximately 88 pounds) are generally dosed according to the official adult dosing regimens. Specific pediatric considerations are usually reserved for smaller children based on weight.


Q: How is the safety of Clamoxol Duo monitored after it is released to the public?

A: The official reporting of adverse events includes post-marketing surveillance data. This is a system used to continuously collect and assess new safety information from patients and healthcare professionals after the product has been made available to the public.


Q: What happens if I accidentally take more Clamoxol Duo than intended?

A: Regulatory documents state that an overdose may lead to gastrointestinal symptoms or disturbances in the body's fluid or electrolyte balance. If this occurs, official guidance indicates that prompt medical attention is appropriate.


Q: Can Clamoxol Duo make me sensitive to the sun?

A: Official adverse reaction lists for this medicine do not generally include photosensitivity (increased sun sensitivity) as a common or known side effect.


Q: Is Clamoxol Duo known to be effective against viral infections?

A: No, the medicine is a combination antibiotic intended only for the treatment of specific bacterial infections. It is not effective against infections caused by viruses, such as the common cold or influenza (the flu).


Q: Are there any common food or drink restrictions with Clamoxol Duo?

A: Official guidance instructs that the oral form of the medicine must be taken at the start of a meal. This is done to ensure the best possible absorption of the medicine's components and to help reduce the potential for stomach upset.


Q: Can Clamoxol Duo cause stomach upset?

A: Yes, official documents list common gastrointestinal side effects, including diarrhea, nausea, and vomiting. Taking the medicine at the start of a meal is recommended to help improve how well the medicine is tolerated.


Q: Can children use Clamoxol Duo, and what are the general considerations?

A: The medicine is approved for use in pediatric patients. However, the dosing for children under 40 kg is precisely calculated based on body weight, and some formulations are generally not recommended for infants under 12 weeks of age.


Q: Is there a link between Clamoxol Duo and yeast infections?

A: Yes, official documentation lists vaginitis, which is commonly associated with yeast overgrowth, as a common adverse reaction that can occur with the use of this medicine.


Q: Are there specific symptoms that mean I should stop taking Clamoxol Duo and seek help?

A: Yes. Severe reactions listed in official documents, such as signs of a serious allergic reaction, severe skin reactions, or symptoms suggesting liver problems (like jaundice), require immediate discontinuation and prompt medical attention.


Q: What is the difference between Clamoxol Duo and Amoxicillin alone?

A: Clamoxol Duo includes clavulanic acid, which is not an antibiotic itself but serves to protect the amoxicillin component. This protection is necessary because clavulanic acid neutralizes bacterial enzymes, allowing the amoxicillin to work effectively against a wider range of resistant bacteria.


Q: Can Clamoxol Duo affect blood tests?

A: Yes, the medicine is known to interfere with certain laboratory tests. Specifically, it may cause false-positive results in non-enzymatic urine glucose tests and may also affect the results of blood coagulation tests.

Advertisements

How should Clamoxol Duo be stored and disposed of?

Storage and Handling Requirements

The official storage conditions for Clamoxol Duo vary significantly by formulation:

  • Tablets and Dry Powder: Must be stored at Controlled Room Temperature (20^circC to 25^circC), protected from excessive moisture. Keep the product in the original, tightly closed container and out of direct light.
  • Reconstituted Suspension: The liquid form must be stored in a refrigerator and must not be frozen.

Stability and Disposal

The reconstituted oral suspension is stable for only 10 days when refrigerated and must be discarded after this period, even if some medicine remains.

All forms must be kept out of the sight and reach of children.

Dispose of unused or expired medicine according to local requirements. To protect the environment, do not dispose of this product into wastewater (sinks or toilets).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clamoxol Duo found in:

A-Z Index: